FDA Clears Test for Detecting HIV Drug-Resistant Mutations
The test may help clinicians tailor HIV therapy for their patients.
The test may help clinicians tailor HIV therapy for their patients.
The FDA has approved a supplemental NDA for Xofluza for the treatment of acute, uncomplicated influenza in patients aged 12 years and older.
The FDA has approved Descovy for HIV-1 PrEP in at-risk adults and adolescents (≥35kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at-risk from receptive vaginal sex.
The FDA has granted Fast Track designations to both the oral and intravenous formulations of fosmanogepix for 7 antifungal indications.
An investigational mRNA vaccine to prevent Zika virus infection has been granted Fast Track designation by the FDA.